Revolution Medicines (RVMD.US) announced positive results from a Phase 1b clinical trial of its broad-spectrum RAS inhibitor, RMC-6236.

Revolution Medicines (RVMD.US) announced positive results from its Phase 1b clinical trial of its pan-RAS inhibitor RMC-6236. Analysis showed that RMC-6236 as a single agent prolonged median progression-free survival (PFS) to 8.1 months and achieved near 90% disease control rate (DCR) in patients with KRAS G12X mutation. KRAS G12X refers to the conversion of glycine at residue 12 of the KRAS protein to another amino acid due to a genetic mutation. The Company is preparing to initiate a global randomized Phase 3 trial of the drug as a pipeline therapy for patients with PDAC.

According to Revolution Medicines, RMC-6236 is the first-in-class targeted therapy for all major RAS mutant cancers. RAS mutations are the major driver of PDAC disease progression.

Cancer cells driven by RAS mutations account for up to 30% of all human cancers, most notably in PDAC, NSCLC and CRC. RMC-6236 is an oral, selective inhibitor of mutant and wild-type RAS in the GTP-bound (active, ON) state.